TAG:
Fee-for-service
Fee-for-service has long been the primary payment model for clinical laboratories and pathology groups. Fee-for-service (FFS) is a payment model in which services are paid for as itemized in the provider’s invoice. It gives an incentive for physicians to provide more treatments because payment is dependent on the quantity of care, rather than quality of care. Similarly, patients are incentivized to welcome any medical service that might not be necessary. Insurance companies shield themselves against ruin by setting cover limits for every beneficiary.
FFS raises costs, discourages the efficiencies of integrated care, and a variety of reform efforts have been attempted, recommended, or initiated to reduce its influence (such as moving towards bundled payments and capitation).
Medicare Parts A (hospital insurance) and B (optional insurance that covers physician, outpatient hospital, home health, laboratory tests, durable medical equipment, designated therapy, outpatient prescription drugs, and other services not covered by Part A) are FFS programs. Medicare processes over one billion FFS claims per year.
As part of the ongoing drive to cut healthcare costs, this model is gradually being phased out by payers and healthcare organizations in favor of value-based payment models, such as pay-for-performance programs and accountable care organizations that are intended to cap costs and spread financial risk among providers, while encouraging coordination of care, disease prevention and better management of chronic conditions. This is seen as a threat to the survival of clinical labs, which expect to see far fewer tests ordered by healthcare providers.
The Clinical Laboratory Management Association is working to help labs navigate these changes. “As fee-for-service reimbursement gives way to bundled reimbursement and per-member-per-month payment, labs will only be successful if they add value to physicians by helping them diagnose disease earlier and more accurately,” says CLMA President Paul Epner.
CLMA has named this program “Increasing Clinical Effectiveness,” or ICE. THE DARK REPORT is one of CLMA’s partners in this effort.
“Our hope is that ICE is a catalyst that helps lab administrators, pathologists, and medical laboratory scientists broaden the focus of their laboratory beyond operational efficiency to include measurable impact on positive patient outcomes,” says Epner.
Market Forces Cause Detroit’s Lab Network To Launch Operations
CEO SUMMARY: Joint Venture Hospital Laboratories’ success rests on an essential fact: it exists to respond to marketplace demands. The network links laboratory operations of 24 hospitals owned by eight integrated delivery systems in Greater Detroit. Not only is it the oldest continuousl…
To Protect Pathology Profits: Understand Managed Care
CEO SUMMARY: On November 8, 1997, THE DARK REPORT convened a private symposium restricted only to pathologists. The sole purpose of this event was to identify how pathologists could preserve and enhance their income. Within the confidential setting of a plush resort in Scottsdale, Arizona…
“State of Lab Industry” Reveals Radical Change
CEO SUMMARY: Pick your trend: declining reimbursement, consolidation, clinical integration, downsizing, and capitated reimbursement. These trends all continued to shape the way laboratories organized to provide services. But 1997’s wildcard was the federal government. Between investigat…
UroCor, Inc.; Histology & AP.
UROCOR, INC. MATCHES THERAPEUTICS WITH DIAGNOSTICS With the recent signing of a co-promotion agreement with Zeneca Pharmaceuticals, UroCor, Inc. is positioned to offer therapeutics as a complement to its diagnostic testing. Based in Oklahoma City, UroCor is a fast-growing c…
Hitting Financial Bottom
During the last three years, financial news from the clinical laboratory industry has generally been bad. Two things attracted the media’s attention. Multi-million dollar Medicare fraud settlements involving laboratories got widespread notoriety. Financial losses at public laboratories attracted le…
Pathology As A Business: Experts Highlight Issues
CEO SUMMARY: A select group of business-minded pathologists broke new ground last week in Scottsdale, Arizona. Candid discussion about the profession’s most sensitive issues provoked a variety of strategies. Among the topics were declining reimbursement, arbitrary contract pricing for A…
California’s Rumor Mill Links LabCorp & Unilab
CEO SUMMARY: Continued financial pressure on all laboratories operating in California leads some industry observers to believe that Laboratory Corporation of America and Unilab might be considering some kind of deal between the two companies. Senior executives at both laboratories say suc…
How AmeriPath Will Alter Pathology Marketplace
CEO SUMMARY: Few pathologists realize how much impact AmeriPath’s business activities will have upon the profession of pathology. Regardless of AmeriPath’s ultimate success or failure, it will bring about irrevocable change to the pathology industry. As the harbinger of such change, A…
Innovative Approach Promises Integration of Clinical Lab Data
CEO SUMMARY: Any laboratory executive with several years in the business has confronted the limitations of laboratory information system (LIS) software. For a variety of reasons, LIS software seldom delivers the full range of benefits and cost-effectiveness sought by laboratories. But in …
Joint Venture In Phoenix To Be Copied Elsewhere
CEO SUMMARY: Look for the Quest-Sonora joint venture to be followed by others in coming months. Competition and marketplace realities are forcing the three national laboratories to respond with groundbreaking strategies. Hospital laboratory partners in these deals can reap significant ben…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.